ViiV Healthcare
Five Moore Drive
Research Triangle Park
North Carolina
27709-3398
United States
Tel: 877-844-8872
Website: http://www.viivhealthcare.com/
135 articles about ViiV Healthcare
-
ViiV Healthcare Announces Superior Efficacy of Investigational, Long-Acting Injectable Formulation of Cabotegravir Dosed Every Two Months Over Daily Oral PrEP
7/7/2020
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that data presented from the HIV Prevention Trials Network (HPTN) 0
-
ViiV Healthcare Announces US FDA Approval for Rukobia (fostemsavir), a First-in-Class Treatment for HIV in Adults With Few Treatment Options Available
7/2/2020
In a phase III study, a majority (60%) of heavily treatment-experienced adults randomized to receive Rukobia with an optimized background therapy achieved and maintained viral suppression through 96 weeks, addressing a critical unmet need LONDON--( BUSINESS WIRE )-- ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration
-
The U.S. Food and Drug Administration (FDA) approved ViiV Healthcare’s Tivicay PD (dolutegravir) in combination with other antiretroviral drugs for children with HIV.
-
ViiV Healthcare announces US FDA approval of the first-ever dispersible tablet formulation of dolutegravir, Tivicay PD, a once-daily treatment for children living with HIV
6/12/2020
ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) has approved Tivicay PD (dolutegravir) tablets for oral suspension, which are used in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type
-
Clinical Catch-Up: May 18-22
5/26/2020
Non-COVID-19 clinical trial updates are outweighing COVID-19 studies, particularly with the American Society of Clinical Oncology meeting coming up soon. Here’s a look. -
AHF Welcomes ViiV’s Success with Injectable HIV Prevention Medication
5/20/2020
Cabotegravir (CAB LA), administered by injection every two months, was shown to be 69% more effective than daily pills in preventing HIV acquisition
-
Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP
5/18/2020
Interim analysis from HPTN 083 study shows investigational, long-acting injectable cabotegravir (CAB LA) administered every two months is 69% more effective than daily pills in preventing HIV acquisition
-
ViiV Halts HIV Prevention Trial Early; Data Shows Asset is 69% More Effective Than Standard of Care
5/18/2020
The results set up the potential for regulatory approval. -
ViiV Healthcare announces £3 million global fund to research the impact of COVID-19 on the HIV community and fill gaps in prevention, treatment and care during the pandemic
4/27/2020
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced the creation of the Global HIV and COVID-19 Emergency Response Fund. The £3 million fund will make available critical financial resources for research projects to study the medical and scientific impact COVID-19 is having on people living with HIV and community-based grants to help addr
-
BioSpace takes an in-depth look at the human immunodeficiency virus including research, drugs in the pipeline and treatments. Check out the free downloadable report.
-
ViiV Healthcare Announces First Global Regulatory Approval of CABENUVA; the First Complete, Long-acting, Regimen for the Treatment of HIV
3/20/2020
Simultaneous approval of VOCABRIA (cabotegravir oral tablets), for short-term treatment in conjunction with CABENUVA (cabotegravir and rilpivirine extended-release injectable suspensions), also granted by Health Canada CABENUVA reduces treatment dosing days from 365 to 12 per year
-
Clinical Catch-Up: March 9-13
3/16/2020
Although news of the COVID-19 pandemic has tended to dominate the news cycle, including for the biopharma industry, there were a number of clinical trial announcements last week. Here’s a look. -
ViiV Healthcare presents positive long-term data from phase III study demonstrating efficacy and safety of cabotegravir and rilpivirine, its investigational, long-acting, injectable treatment regimen in adults living with HIV-1
3/9/2020
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, presented 96-week data from its global phase III FLAIR study of the investigational, long-acting, injectable, 2-drug regimen of ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine for the treatment of HIV.
-
ViiV Healthcare and UNC-Chapel Hill announce five-year renewal of innovative HIV cure partnership
3/9/2020
Unique public-private collaboration provides continued funding for HIV Cure Center and Qura Therapeutics, the joint venture that brings academic and pharmaceutical research scientists together
-
ViiV Healthcare initiates study with the University of South Carolina to evaluate the benefits of ride-sharing services on improving access to care for people living with HIV
3/2/2020
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced the initiation of a study in partnership with the University of South Carolina’s (USC) Ryan White Program in Columbia
-
ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available
1/10/2020
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced the submission of a marketing authorisation application (MAA) to the European Medicines Agency (EMA) seeking approval of fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV-1 infection.
-
The FDA issued a Complete Response Letter for its combination treatment of cabotegravir and rilpivirine.
-
ViiV Healthcare receives complete response letter from US FDA for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV
12/21/2019
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, received a complete response letter from the US Food and Drug Administration regarding its application for cabotegravir and rilpivirine long-acting regimen for treatment of HIV-1 infection in virologically suppressed adults..
-
ViiV Healthcare submits New Drug Application to the FDA for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available
12/5/2019
Fostemsavir is being developed for use in combination with other antiretroviral agents in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection who are unable to form a suppressive regimen due to resistance, intolerance or safety considerations.
-
ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational “bNAb” with potential for long-acting HIV treatment and prevention
11/21/2019
Broadly neutralising antibodies are antibodies that can recognise and block the entry of different strains of HIV into healthy cells.